Cost Benefit Analysis of Clinical Pharmacist Interventions in Medical Intensive Care Unit in Palestine Medical Complex: Prospective Interventional Study

Overview

Journal Saudi Pharm J

Specialty Pharmacy

Date 2023 Jan 5

PMID 36601501

Authors

Aseel Houso

Motasem Hamdan

Hiba Falana

Affiliations

Soon will be listed here.

Abstract

Background: Clinical pharmacy services in the critical health care settings have expanded dramatically.Study problem.Clinical pharmacy services have limited implementation in Palestine. Many intensive care units (ICUs) patients do not get the intended beneficial effects of their treatment due to treatment related problems and their consequent cost burden.

Aim: To evaluate the impact of the clinical pharmacist interventions on costs of care and safety of patient by assessing treatment related problems among medical ICUs patients in Palestine.

Methodology: A prospective interventional study was conducted at medical ICU of the major public hospital in Ramallah city over a 4-month period (between September and December 2020). Patients were randomly assigned to either an intervention or a control group (With / without clinical pharmacist involvement). Treatment related problems were identified in both study groups by the clinical pharmacist, but interventions were only provided to the intervention group. The total economic benefit included both cost savings from intervention and cost avoidance from preventable adverse drug events (ADEs) resulted from CP interventions. The primary outcomes with the clinical pharmacist interventions were net benefit and benefit to cost ratio, which were calculated using previously published methodologies and adjusted to the Palestinian settings. The analysis of CP interventions acceptance by physicians was performed.

Results: During the 4-month study period, the 117 patients admitted to the ICU were included into the analysis; 66 patients in the intervention group and 51 in the control group. The interventions made by a clinical pharmacist resulted in direct cost saving of NIS8,990.05 ($2799.63) and cost avoidance of NIS22,087.5 ($ 6878.37). Translated into a net savings of NIS188.35 ($58.65) per intervention and NIS470 ($146.36) per patient. Comparison of benefits (NIS31,077.55) ($9678.00) and costs (NIS19,043.928) ($5930.55) indicate a net economic benefit to the institution of (NIS 12,033.623) ($3747.44) and a benefit cost ratio of 1.63.

Conclusion: Integrating a clinical pharmacist in the ICU team was investment that resulted in benefits in term of cost saving and cost avoidance.

Citing Articles

Clinical pharmacist-led medication reconciliation supplemented with medication review in admitted patients with chronic kidney disease: a cost-benefit analysis.

Altawalbeh S, Sallam N, Al-Khatib M, Alshogran O, Bani Amer M BMJ Open. 2025; 15(2):e087232.

PMID: 40010830 PMC: 11865755. DOI: 10.1136/bmjopen-2024-087232.

Clinical pharmacists' interventions for preventing adverse events in critically ill neonates in Qatar: an economic impact analysis.

Yakti O, Al-Badriyeh D, Rijims M, Abdelaal M, Alsoukhni O, Al Hail M J Pharm Policy Pract. 2024; 17(1):170-190.

PMID: 38236554 PMC: 10793632. DOI: 10.1080/20523211.2023.2291508.

References

Gallagher J, Byrne S, Woods N, Lynch D, McCarthy S . Cost-outcome description of clinical pharmacist interventions in a university teaching hospital. BMC Health Serv Res. 2014; 14:177. PMC: 4020601. DOI: 10.1186/1472-6963-14-177. View

Rottenkolber D, Hasford J, Stausberg J . Costs of adverse drug events in German hospitals--a microcosting study. Value Health. 2012; 15(6):868-75. DOI: 10.1016/j.jval.2012.05.007. View

Aljbouri T, Alkhawaldeh M, Abu-Rumman A, Hasan T, Khattar H, Abu-Oliem A . Impact of clinical pharmacist on cost of drug therapy in the ICU. Saudi Pharm J. 2013; 21(4):371-4. PMC: 3824941. DOI: 10.1016/j.jsps.2012.12.004. View

Nesbit T, Shermock K, Bobek M, Capozzi D, Flores P, Leonard M . Implementation and pharmacoeconomic analysis of a clinical staff pharmacist practice model. Am J Health Syst Pharm. 2001; 58(9):784-90. DOI: 10.1093/ajhp/58.9.784. View

Touchette D, Doloresco F, Suda K, Perez A, Turner S, Jalundhwala Y . Economic evaluations of clinical pharmacy services: 2006-2010. Pharmacotherapy. 2014; 34(8):771-93. DOI: 10.1002/phar.1414. View

Mahmoodpoor A, Kalami A, Shadvar K, Entezari-Maleki T, Hamishehkar H . Evaluation of Clinical Pharmacy Services in the Intensive Care Unit of a Tertiary University Hospital in the Northwest of Iran. J Res Pharm Pract. 2018; 7(1):30-35. PMC: 5934984. DOI: 10.4103/jrpp.JRPP_17_82. View

Kopp B, Erstad B, Allen M, Theodorou A, Priestley G . Medication errors and adverse drug events in an intensive care unit: direct observation approach for detection. Crit Care Med. 2006; 34(2):415-25. DOI: 10.1097/01.ccm.0000198106.54306.d7. View

Al-Qudah R, Al-Badriyeh D, Al-Ali F, Altawalbeh S, Basheti I . Cost-benefit analysis of clinical pharmacist intervention in preventing adverse drug events in the general chronic diseases outpatients. J Eval Clin Pract. 2019; 26(1):115-124. DOI: 10.1111/jep.13209. View

Leache L, Aquerreta I, Aldaz A, Monedero P, Idoate A, Ortega A . Clinical and economic impact of clinical pharmacist interventions regarding antimicrobials on critically ill patients. Res Social Adm Pharm. 2019; 16(9):1285-1289. DOI: 10.1016/j.sapharm.2019.07.006. View

10.

Leape L, Cullen D, Clapp M, Burdick E, Demonaco H, Erickson J . Pharmacist participation on physician rounds and adverse drug events in the intensive care unit. JAMA. 1999; 282(3):267-70. DOI: 10.1001/jama.282.3.267. View

11.

Hammond D, Gurnani P, Flannery A, Smetana K, Westrick J, Lat I . Scoping Review of Interventions Associated with Cost Avoidance Able to Be Performed in the Intensive Care Unit and Emergency Department. Pharmacotherapy. 2019; 39(3):215-231. DOI: 10.1002/phar.2224. View

12.

Bates D, Spell N, Cullen D, Burdick E, Laird N, Petersen L . The costs of adverse drug events in hospitalized patients. Adverse Drug Events Prevention Study Group. JAMA. 1997; 277(4):307-11. View

13.

Kane-Gill S, Kirisci L, Verrico M, Rothschild J . Analysis of risk factors for adverse drug events in critically ill patients*. Crit Care Med. 2011; 40(3):823-8. PMC: 3581340. DOI: 10.1097/CCM.0b013e318236f473. View

14.

Chen C, Hsiao F, Shen L, Wu C . The cost-saving effect and prevention of medication errors by clinical pharmacist intervention in a nephrology unit. Medicine (Baltimore). 2017; 96(34):e7883. PMC: 5572025. DOI: 10.1097/MD.0000000000007883. View

15.

Reinau D, Furrer C, Stampfli D, Bornand D, Meier C . Evaluation of drug-related problems and subsequent clinical pharmacists' interventions at a Swiss university hospital. J Clin Pharm Ther. 2019; 44(6):924-931. DOI: 10.1111/jcpt.13017. View

16.

Aburuz S, Bulatova N, Yousef A, Al-Ghazawi M, Alawwa I, Al-Saleh A . Comprehensive assessment of treatment related problems in hospitalized medicine patients in Jordan. Int J Clin Pharm. 2011; 33(3):501-11. DOI: 10.1007/s11096-011-9497-y. View

17.

Yasunaga D, Tasaka Y, Murakami S, Tanaka A, Tanaka M, Araki H . Economic contributions of pharmaceutical interventions by pharmacists: a retrospective report in Japan. J Pharm Policy Pract. 2016; 10:2. PMC: 4955163. DOI: 10.1186/s40545-016-0073-7. View

18.

Bosma B, van den Bemt P, Melief P, Van Bommel J, Tan S, Hunfeld N . Pharmacist interventions during patient rounds in two intensive care units: Clinical and financial impact. Neth J Med. 2018; 76(3):115-124. View

19.

Fuchs L, Chronaki C, Park S, Novack V, Baumfeld Y, Scott D . ICU admission characteristics and mortality rates among elderly and very elderly patients. Intensive Care Med. 2012; 38(10):1654-61. PMC: 5718912. DOI: 10.1007/s00134-012-2629-6. View

20.

Michalets E, Creger J, Shillinglaw W . Outcomes of expanded use of clinical pharmacist practitioners in addition to team-based care in a community health system intensive care unit. Am J Health Syst Pharm. 2014; 72(1):47-53. DOI: 10.2146/ajhp140105. View